• PDF / 1,355,554 Bytes
• 10 Pages / 595.276 x 790.866 pts Page_size
• 1 Downloads / 197 Views

DOWNLOAD

REPORT

ORIGINAL ARTICLE – CLINICAL ONCOLOGY

Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer Huijie Zhou1 · Yu Sun2 · Weigang Xiu3 · Jialong Han1 · Lili Zhong1 · Jiaojiao Suo1 · Hao Wei1 · Yan Wang4 · Jiang Zhu3  Received: 1 April 2020 / Accepted: 30 May 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020

Abstract Purpose  Dissociated response (DR, reduction at baseline or increase 

Recommend Documents

Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessm

197 89 435KB

Immune checkpoint inhibitors

178 53 166KB

Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers

162 81 1MB

Immunotherapy in Cancer: Immune Checkpoint Inhibitors; Changing Oncology Treatment Paradigm

145 16 4MB

Biomarkers for Immune Checkpoint Inhibitors

160 50 13MB

Various therapeutic effects of immune checkpoint inhibitors

113 99 214KB

Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors

160 89 559KB

Cardiotoxicity Related to Immune Checkpoint Inhibitors

194 73 391KB

Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors

170 60 840KB

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

144 58 974KB

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

176 76 958KB

MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas

139 11 2MB